What is the Role of Cangrelor in Patients Undergoing PCI?

Author(s): Michal Droppa , Tobias Geisler* .

Journal Name: Current Vascular Pharmacology

Volume 16 , Issue 5 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic events in patients undergoing Percutaneous Coronary Intervention (PCI). However, oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition and very short plasma half-life it allows effective and controllable periprocedural platelet inhibition. It could reduce short-term ischemic events in large randomized clinical trials. The present article reviews the available evidence and application on cangrelor use in clinical practice.

Keywords: Cangrelor, P2Y12-receptor inhibitors, platelet inhibition, coronary artery disease, acute coronary syndrome, percutaneous coronary intervention.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 5
Year: 2018
Page: [484 - 489]
Pages: 6
DOI: 10.2174/1570161116666180117105834
Price: $58

Article Metrics

PDF: 32
HTML: 1
EPUB: 1
PRC: 1